lunes, 17 de junio de 2024
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-primary-advanced-or-recurrent-endometrial-carcinoma?utm_medium=email&utm_source=govdelivery
On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario